Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14457012 | 0.83 | GAA (0.43) | JAK2SIRT1IKBKBMAPTKDM4E | |
| SCHEMBL14457070 | 0.83 | MAP2 (0.47) | JAK2SIRT1IKBKBMAPTKDM4E | |
| SCHEMBL396855 | 0.83 | CA5A (0.50) | IKBKBMAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL399911 | 0.79 | EEF2K (0.39) | JAK2IKBKBMAPTKDM4EALDH1A1 | |
| SCHEMBL14457522 | 0.77 | JAK2 (0.43) | JAK2SIRT1IKBKBKDM4EALDH1A1 | |
| SCHEMBL3619485 | 0.72 | JAK2 (0.52) | JAK2 | |
| SCHEMBL3618450 | 0.71 | SIRT1 (0.42) | PDPK1JAK2RXFP1SIRT1MAPT | |
| SCHEMBL16709352 | 0.71 | SIRT1 (0.50) | RXFP1SIRT1MAPTKDM4EALDH1A1 | |
| SCHEMBL975904 | 0.70 | RXFP1 (0.50) | PDPK1JAK2RXFP1SIRT1MAPT | |
| SCHEMBL12281523 | 0.68 | JAK2 (0.56) | PDPK1JAK2RXFP1TBK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101604-B2 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812018-B2 | inhibitors of I kappa B kinase ( IKK-2) 2-amino-9-methyl-9H-pyrido[2,3-b]indole-3-carboxamide, useful for treating inflammatory diseases and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207997-A1 | Alpha carbolines and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007097981-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207997-A1 | Alpha carbolines and uses thereof | CHRM1, CNR1, CXCR1 | PDPK1 3544/4885JAK2 153/4885RXFP1 59/4885 |
| US-20100311715-A1 | ALPHA CARBOLINES AND USES THEREOF | CHRM1, CNR1, CXCR1 | PDPK1 3544/4885JAK2 153/4885RXFP1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.